PrEP regimens containing Selzentry safe, well-tolerated compared with Truvada

Pre-exposure prophylaxis regimens containing Selzentry were generally safe and well-tolerated compared with Truvada, the standard-of-care PrEP drug, according to the results of a phase 2 trial.

Roy M. Gulick, MD, MPH, professor of medicine and chief of the division of infectious diseases at Weill Cornell Medicine, and colleagues studied four PrEP regimens in at-risk HIV-uninfected men and transgender women who have sex with men and concluded that regimens containing Selzentry (maraviroc, ViiV Heathcare; MVC) “may warrant further study for PrEP,” they wrote in TheJournal of Infectious Diseases.

Read more

You Might Also Like